KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Rigel Pharmaceuticals (RIGL) EBIAT (2016 - 2025)

Rigel Pharmaceuticals has reported EBIAT over the past 16 years, most recently at $268.1 million for Q4 2025.

  • Quarterly results put EBIAT at $268.1 million for Q4 2025, up 1769.22% from a year ago — trailing twelve months through Dec 2025 was $367.0 million (up 1999.08% YoY), and the annual figure for FY2025 was $367.0 million, up 1999.08%.
  • EBIAT for Q4 2025 was $268.1 million at Rigel Pharmaceuticals, up from $27.9 million in the prior quarter.
  • Over the last five years, EBIAT for RIGL hit a ceiling of $268.1 million in Q4 2025 and a floor of -$27.4 million in Q1 2022.
  • Median EBIAT over the past 5 years was -$3.4 million (2023), compared with a mean of $14.1 million.
  • Biggest five-year swings in EBIAT: crashed 169.48% in 2022 and later surged 5887.67% in 2025.
  • Rigel Pharmaceuticals' EBIAT stood at -$22.6 million in 2021, then surged by 106.19% to $1.4 million in 2022, then tumbled by 47.39% to $737000.0 in 2023, then skyrocketed by 1845.86% to $14.3 million in 2024, then soared by 1769.22% to $268.1 million in 2025.
  • The last three reported values for EBIAT were $268.1 million (Q4 2025), $27.9 million (Q3 2025), and $59.6 million (Q2 2025) per Business Quant data.